Stay updated on Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Sign up to get notified when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.

Latest updates to the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.4.2 was added to replace Revision: v3.4.1 on the page. This appears to be a minor site version update not affecting study details.SummaryDifference0.0%

- Check10 days agoChange DetectedFooter revision updated from v3.4.0 to v3.4.1. The change is a minor deployment note and does not modify study content, navigation, or displayed data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoChange DetectedThis update adds a glossary toggle and a revision label (v3.4.0), and adjusts QC-related headers and FEAR Act terminology.SummaryDifference0.1%

- Check32 days agoChange DetectedUpdated page revision from v3.3.3 to v3.3.4 with no visible impact on content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check53 days agoChange DetectedThe study's Locations section has been expanded and reorganized to list participating sites across multiple countries and regions.SummaryDifference3%

- Check82 days agoChange DetectedThe Publications section now notes that PubMed publications are automatically populated and may not be about the study. The revision label changed from v3.2.0 to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to Tivozanib vs Sorafenib in Refractory RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tivozanib vs Sorafenib in Refractory RCC Clinical Trial page.